Top Markets
#1 DogBull DogBull +54.65%
#2 Siren Siren +31.05%
#3 OriginTrail OriginTrail +17.89%
#4 Purr Purr +12.64%
#5 Yield Basis Yield Basis +11.36%
#6 龙虾 (Lobster) 龙虾 (Lobster) +10.15%
#7 Stargate Finance Stargate Finance +8.65%
#8 Cysic Cysic +8.61%
#9 COTI COTI +7.71%
#10 MetYa MetYa +7.40%
Coin of the day
DogBull DogBull
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
3D Medicines Inc. 3D Medicines Inc.

3D Medicines Inc.

1244
Classifica tra le azioni #22092
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a... Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Prezzo delle azioni
$0.38441832
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$94.54M
Variazione (1 giorno)
-12.13%
Variazione (1 anno)
-62.78%
Paese
CN
Scambia 3D Medicines Inc. (1244)

Categoria

Healthcare
Storico del prezzo dell'azione per 3D Medicines Inc. (1244)
Prezzo di chiusura più alto: $0.29 il 2026-08-01

Prezzo di chiusura più basso: $4.83 il 2022-12-01
Storico del prezzo dell'azione di 3D Medicines Inc. dal 2022 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -7.96%
2025 79.45%
2024 -66.17%
2023 -78.29%
2022 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH